DANSKE:OMXCOPDanske Bank A/S Analysis
Data as of 2026-03-10 - not real-time
DKK 323.60
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Danske Bank trades at DKK 323.6, sitting just below its 20‑day SMA of 330.8 and 50‑day SMA of 326, indicating short‑term pressure, while the 200‑day SMA at 286 remains well beneath the current price, confirming a longer‑term bullish backdrop. The RSI of 46.9 suggests the stock is neither overbought nor oversold, and the MACD histogram is negative, signaling bearish momentum in the near term. Nevertheless, the price remains above the identified support at 308.2 and well under the resistance near 347.5, providing a comfortable cushion. The market’s fear‑and‑greed index reads 79.16 – “Extreme Greed” – which has helped lift the stock toward its upside potential of roughly 8 %.
Fundamentally, the bank appears undervalued with a trailing P/E of 11.6 versus an industry average of 17.4 and a forward P/E of 10.4, while delivering a robust dividend yield of 5.33 % on a modest 33.5 % payout ratio, indicating sustainable income. Its low beta of 0.52 and a 30‑day volatility of 27 % point to relatively stable price behavior, and the consensus analyst rating is a “Buy” with a median target of 361 DKK, implying further upside. Strong operating margins (55 %) and a solid ROE of 13 % underpin the valuation case, despite a negative operating cash flow figure. Taken together, the metrics suggest a value‑oriented investment with a growth tilt, making the stock attractive for medium‑ to long‑term investors.
Fundamentally, the bank appears undervalued with a trailing P/E of 11.6 versus an industry average of 17.4 and a forward P/E of 10.4, while delivering a robust dividend yield of 5.33 % on a modest 33.5 % payout ratio, indicating sustainable income. Its low beta of 0.52 and a 30‑day volatility of 27 % point to relatively stable price behavior, and the consensus analyst rating is a “Buy” with a median target of 361 DKK, implying further upside. Strong operating margins (55 %) and a solid ROE of 13 % underpin the valuation case, despite a negative operating cash flow figure. Taken together, the metrics suggest a value‑oriented investment with a growth tilt, making the stock attractive for medium‑ to long‑term investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages
- Bearish MACD histogram
- Strong dividend yield providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to peers (P/E 11.6 vs 17.4)
- Sustainable 5.33% dividend with low payout ratio
- Analyst consensus target implying ~8% upside
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Stable low‑beta profile and solid ROE
- Consistent high dividend yield
- Strong capital base and long‑term bullish trend
Key Metrics & Analysis
Financial Health
Revenue Growth3.50%
Profit Margin40.74%
P/E Ratio11.6
ROE12.95%
ROA0.62%
P/B Ratio1.5
Op. Cash FlowDKK-48246001664
Industry P/E17.4
Technical Analysis
TrendBullish
RSI46.9
SupportDKK 308.20
ResistanceDKK 347.50
MA 20DKK 330.83
MA 50DKK 326.06
MA 200DKK 286.12
MACDBearish
VolumeDecreasing
Fear & Greed Index79.16
Valuation
Target PriceDKK 350.38
Upside/Downside8.28%
GradeUndervalued
TypeBlend
Dividend Yield5.33%
Risk Assessment
Beta0.52
Volatility27.04%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.